Advertisement

Topics

FDA Approves Enzalutamide for Nonmetastatic CRPC

16:11 EDT 13 Jul 2018 | OncLive

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
 

Original Article: FDA Approves Enzalutamide for Nonmetastatic CRPC

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Enzalutamide for Nonmetastatic CRPC"

Advertisement
Quick Search
Advertisement
Advertisement